It is believed by many here, me included, that the generic versions of VASCEPA are not bioequivalent (lab results show this), but more importantly they are not therapeutically equivalent. This can't be proven because by definition generics do not need to preform outcome trials. However, it is presumed that generic versions may not be effective due to peroxidation of the active ingredient because of poor methods in encapsulating the IPE and the use of excipients that may interfere with absorption into the endothelial bilayer. much lab work has been done on mixed EPA/DHA drugs, showing the blunting effect of DHA. It's my belief that oxidation of EPA in the generic capsules are just as putative as DHA in similar drugs.
News 
Market Data 
Discover 
AI
